CDIO vs. ONCY, VOR, FBLG, INKT, GRCE, PASG, DARE, CVKD, IPA, and EGRX
Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Oncolytics Biotech (ONCY), Vor Biopharma (VOR), FibroBiologics (FBLG), MiNK Therapeutics (INKT), Grace Therapeutics (GRCE), Passage Bio (PASG), Daré Bioscience (DARE), Cadrenal Therapeutics (CVKD), ImmunoPrecise Antibodies (IPA), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry.
Cardio Diagnostics vs.
Oncolytics Biotech (NASDAQ:ONCY) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
Cardio Diagnostics has higher revenue and earnings than Oncolytics Biotech.
In the previous week, Cardio Diagnostics had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 3 mentions for Cardio Diagnostics and 2 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.00 beat Cardio Diagnostics' score of -0.72 indicating that Oncolytics Biotech is being referred to more favorably in the media.
6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Oncolytics Biotech presently has a consensus price target of $4.33, suggesting a potential upside of 914.83%. Cardio Diagnostics has a consensus price target of $60.00, suggesting a potential upside of 1,224.50%. Given Cardio Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Cardio Diagnostics is more favorable than Oncolytics Biotech.
Oncolytics Biotech received 157 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 68.51% of users gave Oncolytics Biotech an outperform vote.
Oncolytics Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Oncolytics Biotech's return on equity of -141.15% beat Cardio Diagnostics' return on equity.
Oncolytics Biotech has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.12, meaning that its share price is 212% more volatile than the S&P 500.
Summary
Cardio Diagnostics beats Oncolytics Biotech on 9 of the 15 factors compared between the two stocks.
Get Cardio Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardio Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CDIO) was last updated on 6/11/2025 by MarketBeat.com Staff
